Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial.

@article{Browman1990ModulationOT,
  title={Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial.},
  author={George P. Browman and Michael David Goodyear and Mark Norman Levine and Robert Vorley Russell and Stuart D. Archibald and Jane M. Young},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1990},
  volume={8 2},
  pages={
          203-8
        }
}
Randomized trials comparing high-dose methotrexate (HDMTX) plus leucovorin (LV) with standard-dose methotrexate (SDMTX) have not detected a therapeutic advantage for the HDMTX arm despite compelling evidence from experimental systems. We hypothesized that these negative trials might reflect modulation of the antitumor effect of methotrexate (MTX) by LV. To test this we randomized 61 patients with locally advanced and recurrent squamous cell head and neck cancer to receive SDMTX (40 mg/m2 weekly… CONTINUE READING
BETA

Similar Papers

Loading similar papers…